British Biotech Pharmaceuticals Limited

Paul Raymond Beckett

Mark Whittaker

Michael George Hunter

Zoe Marie Spavold

John Martin Clements

Lisa Marie Pratt

Steven Launchbury

Gilles Denis Pain

A method for the treatment of bacterial infections in humans and non-human mammals, which comprises inhibiting bacterial growth by administering to a subject an antibacterially effective dose of a compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof: 

Hydroxamic acid derivatives as antibacterials

Compounds of formula (I) are antibacterial or antiprotozoal agents for treatment of infections in humans and non-human mammals, wherein: Z represents a radical of formula &#x2014;N(OH)CH(&#x2550;O) or formula C(&#x2550;O)NH(OH); Rrepresents hydrogen, methyl or trifluromethyl, or except when Z is a radical of formula &#x2014;N(OH)(&#x2550;O), a hydroxy, halo or amino group; Rrepresents a group R&#x2014;(X)-(ALK)&#x2014; wherein R, ALK, X, m and n are as defined in the specification; Rrepresents hydrogen, (C&#x2013;C) alkyl or phenyl(C&#x2013;C)alkyl-; and Rand Rare as defined in the specification. 

N-formyl hydroxylamine derivatives as inhibitors of bacterial polypeptide formylase for treating microbial infections

A method for the treatment of bacterial infections in humans and non-human mammals, which comprises inhibiting bacterial growth by administering to a subject an antibacterially effective dose of a compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof:

Growing community of inventors

Oxford, United Kingdom

Paul Raymond Beckett